7 withdrawn. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Withdrawn 7 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HCV Post-Exposure Prophylaxis for Health Care Workers Sofosbuvir/Velpatasvir Treatment for 14 days - Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-08-13 | 2020-01-21 | |
| Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant Zepatier, Zepatier plus Sofosbuvir - Renal Failure Chronic, Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2018-10-01 | 2018-12-20 | |
| Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet sofosbuvir/velpatasvir tablet, sofosbuvir/velpatasvir crushed - HCV | Phase 4 | Withdrawn | Radboud University Medical Center | 2018-04-01 | 2020-12-07 | |
| A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A elbasvir/grazoprevir, Sofosbuvir, Ribavirin - HCV | Phase 4 | Withdrawn | Fundacion SEIMC-GESIDA | 2017-07-01 | 2018-06-08 | |
| DAA in the Risk of Recurrence After Curative Treatment of HCC Ledipasvir 90mg/Sofosbuvir 400 mg, Ribavirin - Hepatocellular Carcinoma | Phase 4 | Withdrawn | Taipei Veterans General Hospital, Taiwan | 2016-11-01 | 2017-08-07 | |
| Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 Simeprevir, Sofosbuvir - PT-NANBH | Phase 4 | Withdrawn | Stanford University | 2015-09-01 | 2016-10-13 | |
| A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Sofosbuvir + Simeprevir - Hepatitis C, Chronic, HIV CDC Category A1 | Phase 4 | Withdrawn | University of California, San Francisco | 2014-08-01 | 2019-06-13 |
Hepatitis C (4) · Hepatitis C, Chronic (2) · Carcinoma, Hepatocellular (1) · Needlestick Injuries (1) · Pressure Ulcer (1) · Recurrence (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Massachusetts General Hospital (2) · Fundacion SEIMC-GESIDA (1) · Radboud University Medical Center (1) · Stanford University (1) · Taipei Veterans General Hospital, Taiwan (1) · University of California, San Francisco (1)
United States (4) · Germany (1) · Netherlands (1) · Spain (1)
Raymond Chung, MD (2) · Anne Luetkemeyer, MD (1) · Mindie H Nguyen, MD, MAS (1) · Yi-Hsiang Huang, MD, PhD (1)